Finally, apixaban, also a direct factor Xa inhibitor, showed in the AVERROES trial favorable results compared to aspirin in patients non suitable for warfarin (55% reduction in stroke and systemic embolism and 21% reduction in death, with similar major hemorrhage) [36], and in the ARISTOTLE trial superiority to warfarin in terms of stroke and systemic embolism (21% reduction), major hemorrhage (31% reduction) and death (11% reduction) [37]. Here, F10 is linked to stroke disorder.